Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

被引：0
|
作者：
Andrew D. Simmons
Minh Nguyen
Elias Pintus
机构：
[1] Translational Medicine,
[2] Clovis Oncology,undefined
[3] Inc.,undefined
[4] Berkshire Cancer Centre,undefined
[5] Royal Berkshire NHS Foundation Trust,undefined
[6] Guy’s Hospital,undefined
来源：
BMC Cancer | / 20卷
关键词：
BRCA; Prostate cancer; PARP inhibitor; Poly (ADP-ribose) polymerase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
    Simmons, Andrew D.
    Nguyen, Minh
    Pintus, Elias
    BMC CANCER, 2020, 20 (01)
  • [2] Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
    Barber, Louise J.
    Sandhu, Shahneen
    Chen, Lina
    Campbell, James
    Kozarewa, Iwanka
    Fenwick, Kerry
    Assiotis, Ioannis
    Rodrigues, Daniel Nava
    Reis Filho, Jorge S.
    Moreno, Victor
    Mateo, Joaquin
    Molife, L. Rhoda
    De Bono, Johann
    Kaye, Stan
    Lord, Christopher J.
    Ashworth, Alan
    JOURNAL OF PATHOLOGY, 2013, 229 (03): : 422 - 429
  • [3] BRCA2 reversion mutations as a resistance mechanism of olaparib in patients with BRCA2-associated mCRPC
    Takemura, Kohji
    Abe, Ayumi
    Yamanaka, Taro
    Toda, Erisa
    Kono, Haruka
    Ozaki, Haruka
    Kuno, Masahiro
    Okumura, Hiroki
    Yamamoto, Kazumasa
    Watanabe, Shogo
    Kizawa, Rika
    Yamaguchi, Takeshi
    Kobayashi, Marina
    Sekine, Akinari
    Sakaguchi, Kazushige
    Tanabe, Yuko
    Suyama, Koichi
    Urakami, Shinji
    Arai, Masami
    Miura, Yuji
    ANNALS OF ONCOLOGY, 2023, 34 : S1461 - S1462
  • [4] Overcoming resistance to PARP inhibitor in ovarian cancer with BRCA2 reversion mutation
    Zouggari, Nawel
    Wang, Wenwen
    Galy, Sana Intidhar Labidi
    Halazonetis, Thanos
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A346 - A346
  • [5] Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations
    Hutchinson L.
    Nature Reviews Clinical Oncology, 2010, 7 (10) : 549 - 549
  • [6] Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum
    Ganesan, Shridar
    JCO PRECISION ONCOLOGY, 2018, 2
  • [7] Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report
    Hemal, Sij
    DeWitt-Foy, Molly
    Klein, Eric A.
    UROLOGY, 2021, 153 : 129 - 131
  • [8] Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report
    Mahadevia, Himil
    Ponvilawan, Ben
    Al-Obaidi, Ammar
    Buckley, Jennifer
    Subramanian, Janakiraman
    Bansal, Dhruv
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [9] What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib
    Petrylak, Daniel P.
    Watkins, Simon P.
    Loehr, Andrea
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer
    Hobbs, Evthokia A.
    Litton, Jennifer K.
    Yap, Timothy A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (14) : 1825 - 1837
12345